MktsMarkets

Edgewise Therapeutics, Inc.
NASDAQ: EWTXKey statistics
EWTX News
Stories mentioning EWTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 42,651 | 43,594 | 37,480 | 33,558 | 36,757 | 36,370 | 32,222 | 30,680 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 54,115 | 55,979 | 46,858 | 42,610 | 45,959 | 45,540 | 40,432 | 38,107 |
| Operating Income (Loss) | (54,115) | (55,979) | (46,858) | (42,610) | (45,959) | (45,540) | (40,432) | (38,107) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (49,013) | (50,216) | (40,666) | (36,115) | (40,798) | (39,662) | (34,129) | (31,497) |
| Earnings Per Share (Basic) | (0.46) | (0.49) | (0.39) | (0.34) | (0.43) | (0.43) | (0.36) | (0.34) |
| Earnings Per Share (Diluted) | (0.46) | (0.49) | (0.39) | (0.34) | (0.43) | (0.43) | (0.36) | (0.34) |
| Weighted Average Shares Outstanding (Basic) | 107,117 | 102,931 | 105,493 | 104,940 | 95,130 | 92,415 | 93,813 | 93,515 |
| Weighted Average Shares Outstanding (Diluted) | 107,117 | 102,931 | 105,493 | 104,940 | 95,130 | 92,415 | 93,813 | 93,515 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About EWTX
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol EWTX. It last traded at $45.93 (Nov 13, 2026, 4:00 PM ET), up 0.2% on the day. That gives Edgewise Therapeutics a market capitalisation of $5.0B and a price-to-earnings ratio of 5.0.
Over the past 52 weeks EWTX has traded between $19.76 and $48.78.
For the quarter ended Mar 31, 2026 it reported a net loss of $49.0M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$49.0M |
| Dec 31, 2025 | — | -$50.2M |
| Sep 30, 2025 | — | -$40.7M |
| Jun 30, 2025 | — | -$36.1M |
From Edgewise Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…